S'identifier

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.

Insulin remains the cornerstone of treatment for most patients with type 1 and many with type 2 diabetes. Subcutaneous insulin administration is pivotal for achieving near-normal glycemia, but differs from physiological insulin secretion in absorption kinetics and circulation dynamics.

Comprehensive diabetes care encompasses more than glucose management, addressing abnormalities in blood pressure, lipids and detecting and managing diabetes-related complications. The treatment goals are individualized to each patient, considering factors such as the risk of hypoglycemia, life expectancy, age, other medical conditions, and advanced complications of diabetes. Patient attitudes, expectations, resources, support systems, and cost considerations are also considered.

Patients are educated about nutrition, exercise, and medications to lower plasma glucose. The dietary approach differs between type 1 and type 2 diabetes. For type 1 diabetes, the focus is on reduced caloric intake, and insulin dosing. For type 2 diabetes, therapies include weight loss, blood pressure reduction, and atherosclerotic risk. Metabolic surgery has shown promising results in preventing or reversing type 2 diabetes, surpassing medical management efficacy in clinical trials.

Du chapitre 25:

article

Now Playing

25.6 : Diabetes: Management and Pharmacotherapy

Insulin and Hypoglycemic Drugs

189 Vues

article

25.1 : Glucose Homeostasis: Regulation of Blood Glucose

Insulin and Hypoglycemic Drugs

1.1K Vues

article

25.2 : Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

Insulin and Hypoglycemic Drugs

940 Vues

article

25.3 : Insulin: The Receptor and Signaling Pathways

Insulin and Hypoglycemic Drugs

956 Vues

article

25.4 : Pathophysiology of Diabetes

Insulin and Hypoglycemic Drugs

749 Vues

article

25.5 : Diabetes: Symptoms, Diagnosis, and Complications

Insulin and Hypoglycemic Drugs

453 Vues

article

25.7 : Insulin: Biosynthesis, Chemistry, and Preparation

Insulin and Hypoglycemic Drugs

245 Vues

article

25.8 : Insulin Formulations: Types and Delivery

Insulin and Hypoglycemic Drugs

121 Vues

article

25.9 : Insulin: Dosing Regimen and Adverse Effects

Insulin and Hypoglycemic Drugs

103 Vues

article

25.10 : Oral Hypoglycemic Agents: Sulfonylureas

Insulin and Hypoglycemic Drugs

109 Vues

article

25.11 : Oral Hypoglycemic Agents: Biguanides and Glitazones

Insulin and Hypoglycemic Drugs

120 Vues

article

25.12 : Oral Hypoglycemic Agents: Glinides

Insulin and Hypoglycemic Drugs

95 Vues

article

25.13 : Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Insulin and Hypoglycemic Drugs

96 Vues

article

25.14 : Glucagon-like Receptor Agonists

Insulin and Hypoglycemic Drugs

231 Vues

article

25.15 : Dipeptidyl Peptidase 4 Inhibitors

Insulin and Hypoglycemic Drugs

110 Vues

See More

JoVE Logo

Confidentialité

Conditions d'utilisation

Politiques

Recherche

Enseignement

À PROPOS DE JoVE

Copyright © 2025 MyJoVE Corporation. Tous droits réservés.